Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject

• US 20090317836A1
• Filed: 01/30/2007
• Published: 12/24/2009
• Est. Priority Date: 01/30/2006
• Status: Abandoned Application

• Current Assignee: The Scripps Research Institute
• Original Assignee: The Scripps Research Institute
• Inventors: Marrinucci, Dena, Kuhn, Peter
• Application Number:
  US12/223,351
• Publication Number:
  US 20090317836A1
• Time in Patent Office: Days
• US Class Current: 435/7.230
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 2800/56 Staging of a disease; Further complications associated with the disease
• CPC Class Codes: G01N 33/5076 involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/6875 Nucleoproteins

Abstract

Methods are provided for detecting circulating tumor cells in a mammalian subject. Methods of diagnosing cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of metastatic cancer or early stage cancer.

Claims

1. A method for detecting circulating tumor cells in a mammalian subject suspected of having cancer comprising:

obtaining a test sample from blood of the subject, the test sample comprising a cell population,

mounting the test sample on a substrate,

detecting the presence or absence of a first marker in the test sample that selectively binds to the circulating tumor cells,

detecting the presence or absence of a second marker in the test sample that binds to the cell population or a subset of the cell population, and

analyzing the cell population detected by the first and second markers to identify and characterize the circulating tumor cells.

2. The method of claim 1 wherein presence of the circulating tumor cells in the specimen indicates presence of metastatic cancer in the mammalian subject.

3. The method of claim 1 wherein presence of the circulating tumor cells in the specimen indicates presence of early stage cancer in the mammalian subject.

4. The method of claim 1 wherein presence or absence of the circulating tumor cells in the specimen indicates presence of a disease free state or a non-measurable disease state in the mammalian subject.

5. The method of claim 1 wherein presence or absence of the circulating tumor cells in the specimen monitors therapy management during cancer therapy or cancer recovery.

6. The method of claim 1 wherein the cell population is a mixed cell population.

7. The method of claim 1 wherein the substrate is a planar substrate.

8. The method of claim 1 wherein mounting the test sample on the substrate forms a biological monolayer.

9. The method of claim 1 wherein the first marker or the second marker is a fluorescent marker.

10. The method of claim 1 wherein the first marker selectively binds to epithelial cells.

11. The method of claim 10 wherein the first marker is a cytokeratin marker.

12. The method of claim 1 wherein the second marker is a cytologic stain to identify the circulating tumor cell by morphology, size, or nuclear to cytoplasmic ratio.

13. The method of claim 12 wherein the cytologic stain is Wright-Giemsa stain.

14. The method of claim 1 wherein the first marker or the second marker is a cell-specific marker.

15. The method of claim 14 wherein the cell-specific marker is cytokeratin, CD45, M30, chemokine receptor, CXCR1, CXCR4, CD44, CD24, VEGF, EGFR, or HuR.

16. The method of claim 1 wherein the test sample further comprises a cell population sorted by a third marker.

17. The method of claim 16, further comprising sorting the cell population prior to mounting the test sample on the substrate.

18. The method of claim 1 further comprising analyzing the cell population by nuclear detail, nuclear contour, presence or absence of nucleoli, quality of cytoplasm, or quantity of cytoplasm.

19. The method of claim 18 further comprising analyzing the cell population by measuring intact cells with a high nuclear to cytoplasmic ratio, intact cells with a low nuclear to cytoplasmic ratio, early apoptotic cells, or late apoptotic cells, and identifying the circulating tumor cells.

20. The method of claim 1 wherein detecting the first marker further comprises analyzing the cell population by cell attachment to the substrate, scanning the cell population on the substrate by fiber optic array, and imaging the cells by digital microscopy using relocation.

21. The method of claim 20 wherein detecting the second marker further comprises relocating epithelial cells identified by the first marker by digital microscopy.

22. The method of claim 1 wherein presence of the circulating tumor cells in the specimen indicates presence of lymphoma, myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, small-cell lung tumors, primary brain tumors, stomach cancer, colon cancer, pancreatic cancer, urinary bladder cancer, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, cervical cancer, endometrial cancer, adrenal cortical cancer, or prostate cancer.

23. A method of diagnosing cancer in a mammalian subject suspected of having cancer comprising:

obtaining a test sample from blood of the subject, the test sample comprising a cell population,

mounting the test sample on a substrate,

detecting the presence or absence of a first marker in the test sample that selectively binds to the circulating tumor cells,

detecting the presence or absence of a second marker in the test sample that binds to the cell population or a subset of the cell population, and

analyzing the cell population detected by the first and second markers to identify and characterize the circulating tumor cells.

24-46. -46. (canceled)

47. A method of screening a drug candidate compound for treatment of cancer in a mammalian subject,

administering a therapeutically effective amount of the drug candidate compound to the subject suspected of having cancer,

obtaining test samples from blood of the subject before and after treatment with the drug candidate compound, the test samples comprising a cell population suspected of containing circulating tumor cells,

mounting the test samples on a substrate,

detecting the presence or absence of a first marker in the test samples that selectively binds to the circulating tumor cells,

detecting the presence or absence of a second marker in the test samples that binds to the cell population or a subset of the cell population, and

analyzing the cell population detected by the first and second markers to identify the circulating tumor cells in the test samples before treatment with the drug candidate compound compared to after treatment with the drug candidate compound, wherein the presence of a decreased number of the circulating tumor cells in the specimen after treatment compared to a number of the circulating tumor cells in a specimen before treatment indicating effectiveness of the drug candidate compound in treating the cancer in the mammalian subject.

48-63. -63. (canceled)